Breaking News Instant updates and real-time market news.

CLVS

Clovis

$5.67

-0.01 (-0.18%)

, AZN

AstraZeneca

$44.37

-0.41 (-0.92%)

06:44
08/13/19
08/13
06:44
08/13/19
06:44

Clovis downgraded to Neutral from Buy at BofA/Merrill

BofA/Merrill Tazeen Ahmad downgraded Clovis (CLVS) to Neutral and lowered his price target to $7 from $13 after last week's release of positive topline results for its PARP inhibitor Lynparza to treat prostate cancer by the company's competitor AstraZeneca (AZN). The analyst notes that the Lynparza update alters his expectations in the prostate cancer market to assume a two-player landscape from day one, reducing his expectations for Clovis's Rubraca peak sales to $250M from $406M with peak U.S. BRCA penetration of 15%.

CLVS

Clovis

$5.67

-0.01 (-0.18%)

AZN

AstraZeneca

$44.37

-0.41 (-0.92%)

  • 04

    Sep

  • 09

    Sep

  • 16

    Sep

  • 25

    Sep

  • 02

    Oct

CLVS Clovis
$5.67

-0.01 (-0.18%)

06/02/19
PIPR
06/02/19
NO CHANGE
Target $21
PIPR
Neutral
Piper Jaffray still sees modest opportunity in BRCA+ mCRPC for Clovis
Piper Jaffray analyst Joseph Catanzaro notes that Clovis presented data from the TOPARP-B study of olaparib in mCRPC at ASCO, with data in BRCA+ patients performing in-line with data previously reported for both rucaparib and niraparib in this setting, perhaps even marginally better, though patient numbers remain small. Activity for olaparib in non-BRCA patients was underwhelming, consistent with rucaparib and olaparib, he adds. Overall, Catanzaro maintains his view that while rucaparib may be first to file in BRCA+ mCRPC, this is a modest opportunity that is becoming increasingly competitive. The analyst reiterates a Neutral rating and a $21 price target on the shares.
08/01/19
PIPR
08/01/19
NO CHANGE
PIPR
Piper Jaffray cuts price target on Clovis to $11 from $21, stays Neutral
Piper Jaffray analyst Joseph Catanzaro maintained a Neutral rating on Clovis and lowering his price target to $11 from $21 after the company's Q2 earnings results. The analyst noted that the call commentary was "incrementally positive," but also noted that revenue was down quarter-over-quarter and that the comapny continues to incur significant operating expenses, although he noted they are expected to temper going forward. Catanzaro said the risk/reward in the stock was balanced, and that he remains comfortable with a Neutral rating on Clovis.
08/01/19
GUGG
08/01/19
DOWNGRADE
GUGG
Neutral
Clovis downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Michael Schmidt downgraded Clovis to Neutral from Buy.
08/02/19
GUGG
08/02/19
DOWNGRADE
GUGG
Neutral
Clovis downgraded to Neutral on Rubraca sales growth struglles at Guggenheim
As previously reported, Guggenheim analyst Michael Schmidt downgraded Clovis to Neutral from Buy as the company continues to struggle to meaningfully grow Rubraca sales in its approved indication, which is a situation he doesn't believe will improve in the near-term as competitor drugs gain more traction. While Clovis is working toward expanding Rubraca use to other types of cancer, most of these trials won't complete until 2020 and 2021, said Schmidt, who removed his prior $35 price target on the stock.
AZN AstraZeneca
$44.37

-0.41 (-0.92%)

07/11/19
RAJA
07/11/19
NO CHANGE
RAJA
Death of drug rebate rule a win for PBMs and distributors, says Raymond James
After multiple media outlets, including Politico, reported that the Trump Administration has decided to withdraw the drug rebate rule, Raymond James analyst Chris Meekins called the news "a win" for pharmacy benefit managers and drug distributors and "a slight negative" for the pharmaceutical makers. The cost of the proposal to the government was ultimately too high with little guarantee that list prices would go down, said Meekins. However, President Trump hinted something "major" on drug pricing was coming over the next week during his kidney care speech and the analyst thinks the President is planning to move forward with an executive order on pricing. Publicly traded pharmaceutical distributors include McKesson (MCK), Cardinal Health (CAH), Amerisource (ABC) and Patterson (PDCO). Owners of pharmacy benefit managers include CVS Health (CVS), UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI). Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/17/19
RAJA
07/17/19
NO CHANGE
RAJA
Investors shouldn't overreact to drug proposal headlines, says Raymond James
Raymond James analyst Chris Meekins noted that President Donald Trump has indicated an Executive Order on drug pricing is coming soon, but he believes investors "should be cautious not to overreact" to drug related proposal headlines as he "cannot think of a single proposal that was finalized and also survived a court challenge resulting in a negative impact on earnings" yet from the Trump Administration. Given the history of the current White House to date, Meekins said he is increasingly skeptical the Administration will get anything meaningful finalized and overcome legal challenges that will impact drugmakers' earnings before the 2020 election, he tells investors in a healthcare policy note. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/26/19
HCWC
07/26/19
NO CHANGE
HCWC
Amarin prepared to defend patents against Epanova launch, says H.C. Wainwright
After speaking with an intellectual property attorney, H.C. Wainwright analyst Andrew Fein believes Amarin (AMRN) has prepared itself to defend its patents for Vascepa against a possible launch of AstraZeneca's (AZN) omega-3 Epanova. The consultation revealed the FDA's Orange Book includes 25 patents listed for Vascepa, Fein tells investors in a research note. While, according to the IP attorney, Amarin's Orange Book patents do not appear to directly address Epanova, Amarin has a large patent portfolio in this space, says the analyst. Fein points out that Amarin could not hypothetically sue AstraZeneca for patent infringement until Epanova was made, used, or sold in a commercial context. These are not brand-generic circumstances between both companies, he writes. However, Fein thinks Amarin's patents could give it the upper hand and he reiterates a Buy rating on the shares with a $51 price target.
07/29/19
WBLR
07/29/19
NO CHANGE
WBLR
Outperform
Updates 'very positive' for upcoming Pieris presentation, says William Blair
Pieris Pharmaceuticals (PIRS) will present Phase Ib safety and efficacy results with PRS-060, an inhaled IL-4R alpha inhibitor, at the upcoming European Respiratory Society International Congress, held September 28 through October 2, William Blair analyst Matt Phipps tells investors in a research note. The poster presentation to be presented on October 1 is titled, "Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma," the analyst point out. In addition, AstraZeneca (AZN) plans to initiate a Phase II trial with AZD1402/PRS-060 in the second half of this year, according to its recent earnings presentation, adds Phipps. He views these updates as "very positive" for the upcoming presentation, and believes PRS-060 has "significant potential" in the treatment of asthma patients. Phipps keeps an Outperform rating on Pieris Pharmaceuticals.

TODAY'S FREE FLY STORIES

RVLT

Revolution Lighting

$0.34

-0.0124 (-3.57%)

18:10
08/22/19
08/22
18:10
08/22/19
18:10
Hot Stocks
Revolution Lighting discloses additional delisting determination from Nasdaq »

Revolution Lighting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBKC

Iberiabank

$70.16

-0.38 (-0.54%)

18:05
08/22/19
08/22
18:05
08/22/19
18:05
Hot Stocks
Iberiabank CEO Daryl Byrd sells over $840K in company shares »

Iberiabank CEO Daryl Byrd…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

RMNI

Rimini Street

$4.77

-0.11 (-2.25%)

, ORCL

Oracle

$53.18

-0.08 (-0.15%)

18:02
08/22/19
08/22
18:02
08/22/19
18:02
Hot Stocks
San Fang Chemical switches to Rimini Street support for Oracle EBS »

Rimini Street (RMNI)…

RMNI

Rimini Street

$4.77

-0.11 (-2.25%)

ORCL

Oracle

$53.18

-0.08 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$148.26

0.86 (0.58%)

18:01
08/22/19
08/22
18:01
08/22/19
18:01
Hot Stocks
Salesforce says Customer 360 will be huge growth driver over next decade »

Says: Momentum in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 12

    Dec

  • 16

    Dec

AAC

AAC Holdings

$0.60

-0.0327 (-5.17%)

17:57
08/22/19
08/22
17:57
08/22/19
17:57
Hot Stocks
AAC Holdings discloses NYSE listing notice »

AAC Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

17:32
08/22/19
08/22
17:32
08/22/19
17:32
General news
Fed Balance Sheet Level data reported »

Week of 8/21 Fed Balance…

HPQ

HP Inc.

$18.91

-0.04 (-0.21%)

17:30
08/22/19
08/22
17:30
08/22/19
17:30
Hot Stocks
HP Inc. says notebooks accounted for 39% of revenue in Q3 »

Says supplies category…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

17:28
08/22/19
08/22
17:28
08/22/19
17:28
General news
Money Supply M2 Weekly Change data reported »

Week of 8/12 Money Supply…

TRPX

Therapix Biosciences

$2.35

(0.00%)

17:27
08/22/19
08/22
17:27
08/22/19
17:27
Syndicate
Breaking Syndicate news story on Therapix Biosciences »

Therapix Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Shares

$141.38

-0.36 (-0.25%)

17:26
08/22/19
08/22
17:26
08/22/19
17:26
Hot Stocks
SPDR Gold Shares holdings rise to 854.84MT to 851.91MT »

This is the third…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMW

VMware

$148.15

0.11 (0.07%)

17:19
08/22/19
08/22
17:19
08/22/19
17:19
Earnings
VMware sees Q3 adjusted EPS $1.42, consensus $1.57 »

Sees Q3 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

  • 10

    Oct

CRWD

Crowdstrike

$93.04

-3.5 (-3.63%)

, CBLK

Carbon Black

$24.52

1.77 (7.78%)

17:14
08/22/19
08/22
17:14
08/22/19
17:14
Hot Stocks
Crowdstrike lower after Carbon Black acquisition »

Shares of cybersecurity…

CRWD

Crowdstrike

$93.04

-3.5 (-3.63%)

CBLK

Carbon Black

$24.52

1.77 (7.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

HPQ

HP Inc.

$18.91

-0.04 (-0.21%)

17:07
08/22/19
08/22
17:07
08/22/19
17:07
Hot Stocks
HP Inc. says CEO Dion Weisler will step down to deal with family health matter »

Says Enrique Lores, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

NP

Neenah Paper

$66.14

-0.455 (-0.68%)

17:05
08/22/19
08/22
17:05
08/22/19
17:05
Hot Stocks
Neenah Paper CFO sells 7.8K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$18.91

-0.04 (-0.21%)

17:04
08/22/19
08/22
17:04
08/22/19
17:04
Hot Stocks
HP Inc. falls over 5% amid slowdown in printer sales »

Shares of HP Inc. are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

NKE

Nike

$83.27

0.46 (0.56%)

17:03
08/22/19
08/22
17:03
08/22/19
17:03
Periodicals
Michael Avenatti plans subpoenas to prove Nike claims, Bloomberg says »

Attorney Michael Avenatti…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

HPQ

HP Inc.

$18.91

-0.04 (-0.21%)

17:00
08/22/19
08/22
17:00
08/22/19
17:00
Hot Stocks
HP Inc. printing net revenue was down 5% year over year »

Printing net revenue was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

SYY

Sysco

$73.32

1.06 (1.47%)

16:56
08/22/19
08/22
16:56
08/22/19
16:56
Hot Stocks
Sysco director Koerber sells 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 25

    Sep

  • 01

    Oct

PVTL

Pivotal Software

$13.69

0.01 (0.07%)

, CBLK

Carbon Black

$24.52

1.77 (7.78%)

16:54
08/22/19
08/22
16:54
08/22/19
16:54
Earnings
VMware raises FY20 EPS view to $6.54 from $6.49, consensus $6.52 »

Sees Carbon Black (CBLK)…

PVTL

Pivotal Software

$13.69

0.01 (0.07%)

CBLK

Carbon Black

$24.52

1.77 (7.78%)

VMW

VMware

$148.15

0.11 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 04

    Sep

  • 10

    Sep

  • 10

    Oct

AFH

Atlas Financial

$0.41

-0.0323 (-7.29%)

16:53
08/22/19
08/22
16:53
08/22/19
16:53
Hot Stocks
Atlas Financial gives update on ongoing strategic review »

Atlas Financial Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEN

Zendesk

$80.87

0.57 (0.71%)

16:51
08/22/19
08/22
16:51
08/22/19
16:51
Hot Stocks
Zendesk CEO sells 100K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 28

    Aug

  • 09

    Sep

  • 10

    Sep

  • 10

    Sep

  • 13

    Nov

CBLK

Carbon Black

$24.52

1.77 (7.78%)

16:50
08/22/19
08/22
16:50
08/22/19
16:50
Hot Stocks
Breaking Hot Stocks news story on Carbon Black »

Carbon Black trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRS

Amyris

$4.07

-0.25 (-5.79%)

16:45
08/22/19
08/22
16:45
08/22/19
16:45
Hot Stocks
Amyris receives deficiency notification from Nasdaq »

Amyris reported that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

DDS

Dillard's

$56.36

-0.21 (-0.37%)

16:43
08/22/19
08/22
16:43
08/22/19
16:43
Hot Stocks
Dillard's increases quarterly dividend 50% »

Dillard's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAS

Hasbro

$114.35

-1.06 (-0.92%)

16:43
08/22/19
08/22
16:43
08/22/19
16:43
Hot Stocks
Hasbro to acquire Entertainment One in all-cash deal valued at about $4B »

Hasbro and Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.